Facility Opening & Expansion Europe · 5d ago

HTL Biotechnology Opens $16.54 Million HTL8 Polynucleotide Purification Unit at Javené Site in France

HTL Biotechnology inaugurates its €15 million HTL8 production unit in France, expanding pharmaceutical-grade polynucleotide purification capacity for regenerative medicine and other healthcare applications.

RD

Research Desk

· 3 min read

HTL Biotechnology Opens $16.54 Million HTL8 Polynucleotide Purification Unit at Javené Site in France

HTL Biotechnology has inaugurated HTL8, a new production unit dedicated to pharmaceutical-grade polynucleotides, at its Javené site in Ille-et-Vilaine, France.

The facility represents a USD 16.54 million investment and arrives as the company's 2022-2026 investment plan approaches its final year.

HTL Expands Pharmaceutical-Grade Biopolymer Production Capabilities

According to the company, the unit is dedicated to the purification of pharmaceutical-grade polynucleotides and strengthens HTL's industrial capabilities while supporting the development of new applications, particularly in regenerative medicine, ophthalmology, and dermatology, including wound healing.

HTL frames the opening as a structuring step in the group's international development strategy and in the diversification of its biopolymer portfolio, responding to growing global demand for biopolymers intended for the most demanding therapeutic applications.

CEOs Comments Anchor the Facility in a USD 110.28 Million Plan

HTL8 sits within the company's 2022-2026 investment plan of USD 110.28 million, which HTL says has strongly contributed to its international development and portfolio diversification in recent years.

François Fournier, CEO of HTL Biotechnology, emphasized the unit's place within that broader plan.

"This new unit is fully in line with the USD 110.28 million investment plan launched in 2022. We are very committed to monitoring our markets and anticipating their developments by placing customer expectations at the heart of our strategy. Equipping ourselves with the most modern industrial capabilities to live up to our ambitions is key in this context. HTL8 is a perfect illustration of this goal: it anchors in France an industrial excellence capable of shining on a global scale, supporting our customers closely in their markets and contributing, through increasingly innovative pharmaceutical-grade biopolymers, to the healthcare solutions of tomorrow," Fournier declared.

The company positions the new unit as a way of consolidating its premium positioning in the innovative segment of regenerative medicine while supporting the growth of global demand, particularly in Asian markets.

Designed to Meet Demanding Pharmaceutical Standards

HTL8 has been designed to meet demanding industrial and pharmaceutical manufacturing standards.

The company states that the unit combines advanced equipment and automation with enhanced control of critical process parameters and rigorous quality and safety requirements.

HTL presents the facility as reinforcing its positioning as a key player in health innovation and as reflecting its approach to industrial excellence: combining advanced equipment and robust processes with the specialist expertise of the teams operating them.

Raw Materials Drawn From Wild Alaskan Salmon

Polynucleotides are biopolymers made up of chains of nucleotides that are attracting increasing interest for their regenerative properties. According to HTL Biotechnology, these properties include the ability to promote tissue repair, hydration, and improved skin quality.

The company manufactures its polynucleotides from DNA extracted from wild Alaskan salmon milt, a co-product of the salmon industry that is recovered and used as a pharmaceutical raw material.

HTL draws on 45 years of expertise in the production of high-quality biopolymers and describes itself as a visionary and pioneering player in the mastery of polynucleotides.

A French Group Expanding Across Continents

HTL Biotechnology is a French biotech company and describes itself as a world leader in the development and bioproduction of pharmaceutical-grade biopolymers, including Hyaluronic Acid and Polynucleotides.

These biopolymers are used by healthcare companies to develop treatments in cutting-edge therapeutic fields such as ophthalmology, dermatology, medical aesthetics, and rheumatology.

The company recently strengthened its position by acquiring, through its subsidiary HTL Biotechnology Innovation Inc. (HTL BII, based in New Jersey), a recombinant protein platform whose most advanced product is recombinant human collagen type III (rhCOL3), obtained from a world-class scientific research center.

To meet the world's growing need for biopolymers, HTL also has subsidiaries in Asia and is building a neuromodulator production unit in the United States (HTL BMI, in Massachusetts).

Historically based in Javené in Brittany, the company combines production, innovation, R&D, and quality activities on its French site and employs nearly 300 people worldwide.

The inauguration of HTL8, according to the company, anchors pharmaceutical-grade polynucleotide production in France while serving international markets, with a particular emphasis on Asian demand. Press contact for the announcement is Matthieu Laude of APCO.

Tracked in the database

Facility Opening & Expansion · Europe

Category

Facility Opening & Expansion

Region

Europe

Industry

Chemical

Published

13 November 2026

Length

3 min read

Tagged

HTL BiotechnologyPharmaceutical manufacturingPolynucleotide purificationFacility investmentBiopolymers

Live from the tracker

The projects behind these stories

Capacity, capex, stage, contractors and verified contacts for every project we track, updated daily.

LLY - Lebanon Medicine Foundry · Indiana, United States · Not disclosed · On-going / Under Construction LLY - Project Savannah Biomanufacturing Facility · Texas, United States · Not disclosed · Planning LLY - Huntsville Medicines Manufacturing Plant · Alabama, United States · Not disclosed · Planning NOVO-B - Clayton Aseptic and Finished Product Manufacturing Plant · North Carolina, United States · Not disclosed · On-going / Under Construction LLY - Pleasant Prairie Pharmaceutical Manufacturing Facility Expansion · Wisconsin, United States · Not disclosed · Planning EDCL - Gopalganj Vaccine Manufacturing Plant · Dhaka Division, Bangladesh · Not disclosed · Planning FF - Holly Springs Cell Culture Biomanufacturing Plant · North Carolina, United States · Not disclosed · On-going / Under Construction LLY - Leiden Bio Science Park Pharmaceutical Manufacturing Plant · Netherlands · Not disclosed · Planning LLY - Alzey Pharmaceuticals Production Plant · Rhineland-Palatinate, Germany · Not disclosed · On-going / Under Construction BAYN - New Albany Pharmaceutical Manufacturing Plant · Ohio, United States · Not disclosed · Planning LLY - Lebanon Medicine Foundry · Indiana, United States · Not disclosed · On-going / Under Construction LLY - Project Savannah Biomanufacturing Facility · Texas, United States · Not disclosed · Planning LLY - Huntsville Medicines Manufacturing Plant · Alabama, United States · Not disclosed · Planning NOVO-B - Clayton Aseptic and Finished Product Manufacturing Plant · North Carolina, United States · Not disclosed · On-going / Under Construction LLY - Pleasant Prairie Pharmaceutical Manufacturing Facility Expansion · Wisconsin, United States · Not disclosed · Planning EDCL - Gopalganj Vaccine Manufacturing Plant · Dhaka Division, Bangladesh · Not disclosed · Planning FF - Holly Springs Cell Culture Biomanufacturing Plant · North Carolina, United States · Not disclosed · On-going / Under Construction LLY - Leiden Bio Science Park Pharmaceutical Manufacturing Plant · Netherlands · Not disclosed · Planning LLY - Alzey Pharmaceuticals Production Plant · Rhineland-Palatinate, Germany · Not disclosed · On-going / Under Construction BAYN - New Albany Pharmaceutical Manufacturing Plant · Ohio, United States · Not disclosed · Planning